Atea Pharmaceuticals, Inc.
A Boston drug developer that makes oral antiviral medicines for serious viral infections, with its lead program pairing bemnifosbuvir and ruzasvir against hepatitis C. It was founded in 2012 by Jean-Pierre Sommadossi, a co-founder of Pharmasset, the company behind the hepatitis C treatment sofosbuvir, sold as Sovaldi. Sommadossi helped build that earlier drug, and Atea carries forward the same nucleoside antiviral science.
Granted 60.0K
Granted 29.6K
Granted 29.6K
Granted 29.6K
Granted 29.6K · Bought 6.1K
Granted 29.6K
Granted 29.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Corcoran AndreaSee Remarks · 1 transaction | +7.9% | 823.6K | 60.0K | — | — |
| Berger Franklin MDirector · 1 transaction | +5.8% | 536.1K | 29.6K | — | — |
| Lucidi BrunoDirector · 1 transaction | +26.3% | 142.3K | 29.6K | — | — |
| Polsky BruceDirector · 1 transaction | +31.1% | 124.8K | 29.6K | — | — |
| Murphy Polly A.Director · 2 transactions | +41.5% | 121.7K | 29.6K | 6.1K | — |
| Adams Jerome M.Director · 1 transaction | +47.2% | 92.3K | 29.6K | — | — |
| Duncan Barbara GayleDirector · 1 transaction | +47.2% | 92.3K | 29.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +6.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.